1. Field of the Invention
The present invention relates to improvements in the performance of implantable defibrillators, ICDs (Implantable Cardioverter-Defibrillators) and other battery powered medical devices designed to provide high-energy electrical stimulation of body tissue for therapeutic purposes.
2. Description of Prior Art
High-energy battery powered medical devices, such as implantable defibrillators and ICDs are designed to deliver a strong electrical shock to the heart when called upon to correct an onset of tachyarrhythmia. In traditional devices the high-energy pulse is produced by charging one or more high-voltage energy storage capacitors from a low-voltage battery and then rapidly discharging the capacitors to deliver the intended therapy. This concept is widely practiced and disclosed in numerous patents, including U.S. Pat. No. 4,475,551 of Mirowski dated Oct. 9, 1984. Additionally, much clinical data on defibrillation therapy has been collected and published. See, for example, Gregory P. Walcott et al., “Mechanisms of Defibrillation for Monophasic and Biphasic Waveforms,” Pacing and Clinical Electrophysiology, March1994:478; and Andrea Natale et al., “Comparison of Biphasic and Monophasic Pulses,” Pacing and Clinical Electrophysiology, July 1995:1354.
In such devices, the energy is first stored in the electric field within one or more capacitors and subsequently transferred to the body tissue. The voltage waveform of the resulting therapy pulse is therefore constrained to consist of one or more truncated exponential decay shapes because of the fact that the capacitors are charged to store only an amount of energy marginally greater than that which is required to be delivered to the body tissue. The capacitor voltage will therefore be a maximum at the start of the discharge pulse and will decay to a lower value at the terminus of the discharge pulse. Likewise, the capacitor must be recharged after delivery of a therapy pulse before a subsequent therapy pulse can be delivered. This fundamental limitation on the voltage waveform of the discharge pulse has a number of serious shortcomings that limit the efficacy of the medical device and contribute to patient discomfort. Chief among these shortcomings are lack of independent control over the voltage, energy and duration of the therapy pulse and a lack of control over the rapidity at which therapy pulses may be delivered.
The energy stored in any capacitor is given by the relationship E=½*C*V2, so that the two parameters of energy and voltage are not independently controllable. Thus, one technique that is widely practiced to control the amount of energy to be delivered to the body tissue is by limiting the maximum voltage to which the energy storage capacitors are charged.
It is also well known to those skilled in the art that the therapy regimes for most, if not all, defibrillators and ICDs dictate increasing energy levels for subsequent therapy pulses when multiple closely spaced defibrillation pulses are required. This is because an unsuccessful outcome for the first therapy pulse is often indicative that the pulse did not deliver sufficient energy to exceed the defibrillation threshold and more energy must be delivered on a subsequent pulse to increase the chance of a successful outcome. The requirement therefore is to deliver subsequent therapy shocks of increasing magnitude until a successful outcome is achieved.
If the energy storage capacitors are charged only to the energy level dictated for the first therapy pulse, they must be recharged to a higher energy level after a determination is made that the first pulse had an unsuccessful outcome. Conversely, if the energy storage capacitors are fully charged when the need for therapy is first recognized in anticipation of requiring multiple shocks, the first shock delivered would have the most energy, with any subsequent shocks delivering less energy unless the capacitors are fully recharged between pulses. This protocol thus does not eliminate the need to recharge the capacitors between therapy pulses and in many cases wastes energy by charging the capacitors with energy that is not delivered for therapy. In either case, there is some minimum time delay until the first therapy pulse can be delivered and between the delivery of each subsequent therapy pulse because of the need to recharge the capacitors. There is clinical data (R. Gradhaus et al., “Effect of Ventricular Fibrillation Duration on the Defibrillation Threshold in Humans.” Journal of Pacing and Clinical Electrophysiology, 2001; 25:14-19; and S. Windecker et al., “The Influence of Ventricular Fibrillation Duration on Defibrillation Efficacy Using Biphasic Waveforms in Humans,” Journal of The American College of Cardiology, 1999; 33:33-38) that indicates a need for higher levels of defibrillation energy as the time from fibrillation onset to defibrillation shock increases. A significant time delay to defibrillation therapy is also undesirable because of the increasing risk of tissue damage due to lack of blood perfusion with every second that passes while the heart is not beating.
It is to improvements in the delivery of high-energy therapy that the present invention is concerned. In particular, the invention is directed to the provision of programmable voltage waveforms for therapeutic delivery by an implantable defibrillator, ICD or other battery-powered medical device.
It is an object of the invention to provide an implantable medical device that is capable of delivering high-energy electrical therapy with voltage waveforms that are varied and programmable. This implantable medical device is capable of delivering the voltage and energy required for defibrillation of a human heart as well as other modes of therapy requiring less energy.
A further object of the invention is to provide an implantable defibrillator or cardioverter-defibrillator wherein the use of a high-energy/high-voltage battery power source provides for the rapid delivery of defibrillation shocks without the need for delay required to charge high-voltage capacitors.
A further object of the invention is to provide an implantable defibrillator or cardioverter-defibrillator wherein the capability to deliver varied and programmable voltage waveforms provides for improved probability of successful defibrillation with lower levels of delivered energy.
A further object of the invention is to provide an implantable defibrillator or cardioverter-defibrillator wherein the capability to deliver varied and programmable voltage waveforms provides therapy with reduced patient discomfort.
The foregoing objects are achieved and an advance in the art is provided by a programmable voltage-waveform-generating battery power source for implantable medical devices, such as implantable defibrillators and ICDs. The power source includes a high-energy battery system, a waveform control system and a power amplifier that collectively provide the capability to deliver electrical therapy with varied and programmable voltage waveforms. The high-energy battery system supplies prime power to the power amplifier, the output of which is connected to physiologic electrodes for the purpose of delivering electrical therapy. The waveform control system supplies waveform voltage control inputs to the power amplifier.
The high-energy battery system may be constructed with a multiplicity of low-voltage rechargeable cells that are interconnected to provide a medium-to-high voltage source suitable for delivering electrical stimulation therapy to tissue within the human body. For example, the high-energy battery system may utilize rechargeable thin-film lithium cells wherein a multiplicity, e.g. 10-250, of independent cells are fabricated and packaged in a total volume equivalent to the existing energy storage capacitors, i.e. 10 to 20 cm3. The cells are electrically interconnected in either a fixed or dynamically configurable fashion in order to deliver electrical energy at a voltage and current consistent with the maximum requirements for therapy needs to be met by the device in which the power source is implemented. In the case of a defibrillator or ICD, the maximum voltage may be as much as 800 volts at peak currents of 20-30 amperes. For lower energy applications such as muscle or nerve stimulation the maximum voltage and current requirements would be reduced.
The waveform control system has the ability to produce a plurality of waveform control outputs. Each waveform control output corresponds to waveform information stored in a memory of the waveform control system. The waveforms are selectable according to therapeutic requirements. The amplitude of the waveform control output can also be specified to the waveform control system. Waveform slope can also be controlled, and reverse image waveforms can also be generated.
The power amplifier can be implemented using a high-efficiency class D switching mode amplifier that modulates the output of the high-energy battery system according to the waveform control output of the waveform control system. A pulse width/duty cycle control module of the power amplifier is driven by an oscillator to convert the waveform control output into voltage pulses. The voltage pulses are provided to the gate of a field effect transistor whose source is connected to the high-energy battery system and whose drain is connected to a two-pole low-pass output filter. The filter integrates the energy in the voltage pulses over time to provide an amplified output voltage that is proportional to the waveform control output of the waveform control system.
According to one exemplary embodiment of the invention, an implantable defibrillator utilizes an implementation of the inventive power source in which the high-energy battery system provides high-voltage energy to the power amplifier and the latter's output is connected to physiologic electrodes, e.g. a defibrillation catheter. The high-energy battery system is configured such that the individual cells are charged in a parallel circuit arrangement and discharged in a series circuit configuration. The low-voltage recharging energy is provided from a primary cell with high-energy density. These configurations allow recharging at a low voltage potential and discharging at a much higher potential.
According to another exemplary embodiment of the invention, an implantable defibrillator again utilizes an implementation of the inventive power source in which the high-energy battery system provides high-voltage energy to the power amplifier and the latter's output is connected to physiologic electrodes, e.g. a defibrillation catheter. The high-energy battery system is again configured such that the individual cells are charged in a parallel circuit arrangement and discharged in a series circuit configuration. The low voltage recharging energy is provided from a transcutaneous RF induction charging system.
According to yet another exemplary embodiment of the invention, an implantable defibrillator again utilizes an implementation of the inventive power source in which the high-energy battery system provides high-voltage energy to the power amplifier and the latter's output is connected to physiologic electrodes, e.g. a defibrillation catheter. The high-energy battery system comprises a primary or secondary battery assembly that provides high voltage energy to a switching mode amplifier whose output is connected to physiologic electrodes, e.g. a defibrillation catheter. The primary or secondary battery has sufficient total energy to support the total energy requirements of the device throughout the design lifetime of the device.
The foregoing and other features and advantages of the invention will be apparent from the following more particular description of exemplary embodiments of the invention, as illustrated in the accompanying Drawings in which:
Introduction
Turning now to the drawings, wherein like reference numerals indicate like elements in all of the several views,
High-Energy Battery System
The high-energy battery system 20 can be constructed with a multiplicity of low-voltage battery cells that are interconnected to provide a medium-to-high voltage source suitable for delivering electrical stimulation therapy to tissue within the human body. In the case where the power source 10 is implemented in a defibrillator or ICD, the maximum voltage delivered by the high-energy battery system 20 may be as much as 800 volts at peak currents of 20-30 amperes. For lower energy applications such as muscle or nerve stimulation, the maximum voltage and current requirements would be reduced.
By way of example only, the high-energy battery system 20 may utilize rechargeable thin-film lithium cells wherein a multiplicity, e.g. 10-250, of independent cells are fabricated and packaged in a total volume equivalent to the existing energy storage capacitors, i.e. 10 to 20 cm3. Thin-film battery cell construction techniques, such as those disclosed in U.S. Pat. Nos. 6,818,356, 6,517,968, 5,597,660, 5,569,520, 5,512,147 and 5,338,625, and in published application US2004/0018424, can be used to fabricate such cells. The contents of the foregoing patents and patent applications are hereby incorporated herein by this reference.
The multiplicity of cells of the high-energy battery system 20 can be electrically interconnected in either a fixed or dynamically configurable fashion in order to deliver electrical energy at a voltage and current consistent with the maximum requirements for therapy needs to be met by the device in which the power source is implemented. One exemplary connection configuration that may be used to electrically interconnect the multiplicity of cells is disclosed in U.S. Pat. No. 5,369,351. Another exemplary connection configuration is disclosed in commonly-assigned copending application Ser. No. 10/994,565, filed on Nov. 22, 2004 by Wilson Greatbatch et al. for a “High Energy Battery Power Source For Implantable Medical Use.” The contents of the foregoing patent and patent application are hereby incorporated herein by this reference. Additional design options for the high-energy battery system 20 are discussed in more detail below in connection with
Waveform Control System
Turning now to
The digital patterns of data necessary to construct the desired output waveforms are stored within the ROM 43. The data patterns are developed during design of the device and hard coded into the ROM 43, and the total number of patterns that may be generated is limited only by the address space of the ROM 43. Each pattern may be stored in a separate area of the ROM 43 address space and selected by a subset of the address inputs. This selection data is provided from the integral microprocessor system of the device in which the power source 10 is implemented as the digital data labeled “Pattern Select Bits.” If the data is provided in binary format, three bits of data would allow for the selection of 23=8 different waveform patterns, e.g. rectangular, trapezoidal, triangular, Gaussian, sinusoidal. The generation of the patterns is accomplished by sequentially stepping through the ROM 43 address space. Discrete values representative of a piecewise approximation of each waveform are predefined and stored in the ROM 43 at the time of fabrication. The digital outputs of a binary up/down counter 44 are applied to the remaining address inputs of the ROM 43 so that as the counter is incremented or decremented, the predefined digital values representative of the waveform amplitude will be sequentially selected and applied to the digital input of the multiplying D/A converter 42. The up/down counter 44 is capable of incrementing or decrementing as selected by the input labeled “Forward/Backward,” which is another output from the integral microprocessor system of the device in which the power source 10 is implemented. This control input provides for the capability to generate each stored waveform or its mirror image without utilizing additional address space within the ROM 43.
Finally, the rate of change and time duration of each waveform is controlled by the rate at which the up/down counter 44 is incremented or decremented. A variable frequency clock 45 has its output connected to the clock input of the up/down counter 44. The clock frequency is controlled by a digital input value labeled “Rate Control Data” which is also supplied as a control output of the integral microprocessor system of the device.
In summary, the waveform control system 40 depicted in
Turning now to
Power Amplifier
Turning now to
The operation of the class D amplifier is depicted graphically in
The drain voltage of the MOSFET 64 depicted in
Exemplary Implantable Devices
Turning now to
The operation of the implantable device 70 will now be described. During periods of normal syncope in the heart 75, or when very low energy pacing is required, the components of the high-energy system will be dormant. Low level activity will be supported by the primary battery 77 and circuitry within the device control system 76 that is not shown here. At such time that the heart enters an abnormal condition such as tachycardia or fibrillation when higher energy therapy is required, the device control system 76 will detect the need for therapy and select a therapy waveform based upon predetermined thresholds and parameters. The device control system 76 will enable the high-energy battery system 72 by asserting the signals applied to the inputs labeled “Discharge Trigger.” The high-energy battery system 72 will provide high voltage energy to the prime power inputs of the power amplifier 73 that are labeled “+Supply” and “−Supply.” The device control system 76, and particularly the waveform control circuitry therein, will then produce a low amplitude therapy waveform on the output labeled “Waveform Control,” which is supplied as the control input to the power amplifier 73. The power amplifier 73 will reproduce the waveform at a higher power level and supply it to the H-bridge switching network 74. The device control system 76 will simultaneously enable the outputs labeled “Defib Enable” singly or in sequence to cause the H-bridge switching network 74 to connect the power amplifier 73 outputs to the physiologic electrodes. The polarity of the output energy is determined by which of the two “Defib Enable” outputs is enabled by the device control system 76 at any time during any waveform. By this means, the device control system 76 may select a monophasic or biphasic output waveforms depending upon the therapy requirements. In the event that the high-energy battery system 72 requires recharging, the control system 76 will assert the output labeled “Charge Enable” that is supplied as an input to the charge control circuit 71. When this circuit is enabled the charge control circuit 71 will transfer energy from the primary battery 77 to the high-energy battery system 72 to recharge it.
A second exemplary implantable medical device 80 is depicted in
The high-energy battery system 72 is provided with sufficient energy storage capability to provide all required device and therapy power for many months of operation. On a yearly basis or at some other suitable interval, the patient will be required to visit a doctor for a checkup and recharging of the high-energy battery system 72. The doctor will use an extra-corporeal charger/programmer 84 to communicate with the implantable device 80 and to transmit energy to the device for the purpose of recharging the high-energy battery system 72. This charger/programmer 84 conventionally utilizes low frequency/low power RF energy to transmit energy through the patient's skin 83.
Turning finally to
Rationale for Configuration
Most, if not all implantable defibrillators and cardioverter-defibrillators utilize high voltage energy storage capacitors as the means to accumulate an electrical charge and then deliver that charge to the heart tissue in order to simultaneously depolarize enough of the heart cells to stop fibrillation and allow the heart to resume normal sinus rhythm. The selection of high-voltage capacitors for defibrillators came about because of the need to deliver significant amounts of energy in a short period of time. By way of example, most modern ICDs are capable of delivering shocks with a total energy of 30 joules with shock durations of less than 50 milliseconds. No other energy delivery/storage technology has been known or practiced with the capability to store and rapidly deliver this level of energy in a small volume consistent with the requirements for an implantable device.
There is a fundamental shortcoming to defibrillators and ICDs that arises from the use of high-voltage capacitors for energy storage. The heart tissue and surrounding blood are electrically coupled to the defibrillator or ICD by means of physiologic electrodes, and the nature of the tissue is such that a relatively low impedance load is presented to the output of the defibrillator. This load is primarily resistive in nature, and endocardial defibrillation catheters as presently practiced typically present an impedance with respect to the device enclosure on the order of 40 ohms. When defibrillation is required, the high-voltage capacitors are charged to as much as 800 volts and then connected to the catheter/device enclosure to deliver the stored energy to the heart. The resulting voltage/current waveform is a decaying exponential waveform with the highest voltage occurring on the leading edge of the waveform. The first generation of implantable defibrillators provided a single monophasic discharge pulse to achieve defibrillation. Subsequent clinical studies revealed that a higher probability of successful defibrillation could be achieved with lower total energy levels by using a biphasic discharge waveform. The biphasic waveform is typically achieved by interrupting the discharge circuit when roughly 50% of the capacitor energy has been delivered and reversing the polarity of the connection to deliver the remaining stored energy. The significant differences between monophasic and biphasic waveforms are discussed in detail in G. Walcott et al., “Mechanisms of Defibrillation for Monophasic and Biphasic Waveforms”, Journal of Pacing and Clinical Electrophysiology, 18, 478-498, (1994); and A. Natale et al., “Comparison of Biphasic and Monophasic Pulses: Does the Advantage of Biphasic Shocks Depend on Waveshape?”, Journal of Pacing and Clinical Electrophysiology, 19, 1354-1361, (1995). As a result of the extensive research and demonstrated advantages of biphasic waveforms, most modern implantable defibrillators and ICDs deliver biphasic defibrillation shocks.
From a clinical perspective, the ultimate requirement is to achieve successful defibrillation with the lowest level of delivered energy. This is desirable for a number of reasons. From a physiologic perspective, higher shock voltages are required for higher energy, and higher shock voltages (approaching 1000 volts) have been found to cause tissue damage. From the perspective of patient comfort, increased shock voltages cause increased levels of patient pain during defibrillation, leading to increased patient anxiety. One means of providing low-pain defibrillation is proposed in U.S. Pat. No. 6,772,007 of Kroll. In this prior art, the inventor disclosed a method of reducing the peak shock voltage while delivering the same energy by means of multiple energy storage capacitors, switches and a current limiting resistor. While this method claims to provide for successful defibrillation at lower peak defibrillation voltages, it lacks flexibility in waveform control, requires a substantial number of components above and beyond a traditional defibrillator circuit and discards some portion of the stored energy in the current limiting resistor. Finally, achieving successful defibrillation at the lowest possible energy is advantageous to the defibrillator or ICD because the device has a fixed maximum amount of energy available for therapy and device background loads. Decreasing the amount of energy required for each defibrillation reduces the drain on the primary battery and thus provides longer device life.
While the available electronic component technology (until very recently) has dictated the use of capacitive discharge circuits for all implantable defibrillators and most, if not all commercially available external defibrillators, there has been within the medical profession long standing interest in improving defibrillation outcome by means of alternative voltage waveforms. External defibrillation with rectangular, trapezoidal and triangular voltage waveforms was studied on animals at various energy levels in an attempt to identify the most efficacious conditions for successful defibrillation. The results of one study were published by Schuder et al.,“Transthoracic ventricular defibrillation with triangular and trapezoidal waveforms”, Circulation Research, Oct. 1966:689-694. A more generalized analysis of defibrillation physiology is provided by W. Irnich, “The Fundamental Law of Electrostimulation and its Application to Defibrillation”, Journal of Pacing and Clinical Electrophysiology;13:1433-1447. In this article, the author asserts that the lowest defibrillation energy is achieved with a rectangular pulse. More recent studies have been published by B. G. Cleland, “A Conceptual Basis for Defibrillation Waveforms”, PACE; 19: 1186-1195 and R. D. White, “Waveforms for Defibrillation and Cardioversion: Recent Experimental and Clinical Studies”, Current Opinion in Critical Care 10:202-207.
We teach here the combination of a high-energy battery system, a waveform control system and a power amplifier within an implantable medical device to provide the capability to deliver varied and programmable voltage waveforms for the purpose of electrostimulation of tissue, including cardiac defibrillation. A device constructed in accordance with this invention will be capable of delivering therapy rapidly, without the many limitations due to energy storage capacitors, over a continuous range of voltages and energy levels not possible with present devices.
Accordingly, a programmable voltage-waveform-generating battery power source for implantable medical use has been disclosed, and the objects of the invention have been achieved. It will, of course, be appreciated that the description and the drawings herein are merely illustrative, and it will be apparent that the various modifications, combinations and changes can be made of these structures disclosed in accordance with the invention. It should be understood, therefore, that the invention is not to be in any way limited except in accordance with the spirit of the appended claims and their equivalents.
This application claims benefit of the filing date of U.S. Provisional Application No. 60/______, filed on Nov. 30, 2004.